AANA:麻醉前可不可以来一颗PDE5抑制剂?

2016-03-24 zhaoshuang译 MedSci原创

近期美国麻醉护士学会(AANA)称,男性在术前一天不要使用治疗勃起功能障碍的药物!常见的包括伟哥和西力士。知道为什么术前不能吃,不做手术就能吃吗?因为一氧化氮!这些药物里含有能够舒张血管和松弛肌肉的一氧化氮,也是为什么血液可以充到小头里的原因。不过,这些药物在人体内的清除时间超过24小时。所以如果手术前吃了这些药,麻醉风险就会大大升高,麻醉时或使用其他药物时,可能出现血压的急剧下降。所以,男性在术

近期美国麻醉护士学会(AANA)称,男性在术前一天不要使用治疗勃起功能障碍的药物!常见的包括伟哥和西力士。

知道为什么术前不能吃,不做手术就能吃吗?

因为一氧化氮!这些药物里含有能够舒张血管和松弛肌肉的一氧化氮,也是为什么血液可以充到阴茎的原因。不过,这些药物在人体内的清除时间超过24小时。所以如果手术前吃了这些药,麻醉风险就会大大升高,麻醉时或使用其他药物时,可能出现血压的急剧下降。

所以,男性在术前和麻醉医师谈话的时候,要交代清楚药物使用情况,包括治疗勃起功能障碍的药物哟。可别嫌丢脸,生命不是儿戏。只有充分的了解之后,麻醉医师才能更好的制定麻醉计划,患者也才能处在更安全的环境中。

当然,治疗勃起功能障碍的药物只是一个例子,生活中患者正在服用的其他处方药或替代药物,也需要与医师进行充分的沟通。

原始出处:

Men, avoid impotence drugs before surger.MedicalXpress.March 21, 2016

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=128613, encodeId=312d128613d4, content=不错哦,会学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 16 11:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633349, encodeId=859616333497c, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Mon Dec 26 10:16:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984872, encodeId=bd2d19848e201, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Wed Jan 04 12:16:00 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851301, encodeId=40c11851301a9, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri May 13 11:16:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82558, encodeId=e0988255871, content=应该了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sun Apr 24 21:35:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77489, encodeId=923ae7489cf, content=应了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Tue Apr 12 10:41:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76127, encodeId=cca1e612713, content=确实在术前谈话有必要去了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c781709303, createdName=WEIXIN9681ef9b, createdTime=Wed Apr 06 22:04:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446438, encodeId=fea61446438ec, content=<a href='/topic/show?id=2e3016e437' target=_blank style='color:#2F92EE;'>#AAN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1674, encryptionId=2e3016e437, topicName=AAN)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIt6X4iaHW8bDticcBSHUibNWk4Koe2icf0pdIOicSueicR3AKmviaSNPHkf9bCEicRK0anXEu3DjolU2EmkQ/132, createdBy=98ca5217513, createdName=bluefate123, createdTime=Sat Mar 26 08:16:00 CST 2016, time=2016-03-26, status=1, ipAttribution=)]
    2016-09-16 1e10c84am36(暂无匿称)

    不错哦,会学到很多

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=128613, encodeId=312d128613d4, content=不错哦,会学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 16 11:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633349, encodeId=859616333497c, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Mon Dec 26 10:16:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984872, encodeId=bd2d19848e201, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Wed Jan 04 12:16:00 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851301, encodeId=40c11851301a9, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri May 13 11:16:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82558, encodeId=e0988255871, content=应该了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sun Apr 24 21:35:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77489, encodeId=923ae7489cf, content=应了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Tue Apr 12 10:41:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76127, encodeId=cca1e612713, content=确实在术前谈话有必要去了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c781709303, createdName=WEIXIN9681ef9b, createdTime=Wed Apr 06 22:04:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446438, encodeId=fea61446438ec, content=<a href='/topic/show?id=2e3016e437' target=_blank style='color:#2F92EE;'>#AAN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1674, encryptionId=2e3016e437, topicName=AAN)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIt6X4iaHW8bDticcBSHUibNWk4Koe2icf0pdIOicSueicR3AKmviaSNPHkf9bCEicRK0anXEu3DjolU2EmkQ/132, createdBy=98ca5217513, createdName=bluefate123, createdTime=Sat Mar 26 08:16:00 CST 2016, time=2016-03-26, status=1, ipAttribution=)]
    2016-12-26 AspirantSuo
  3. [GetPortalCommentsPageByObjectIdResponse(id=128613, encodeId=312d128613d4, content=不错哦,会学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 16 11:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633349, encodeId=859616333497c, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Mon Dec 26 10:16:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984872, encodeId=bd2d19848e201, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Wed Jan 04 12:16:00 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851301, encodeId=40c11851301a9, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri May 13 11:16:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82558, encodeId=e0988255871, content=应该了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sun Apr 24 21:35:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77489, encodeId=923ae7489cf, content=应了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Tue Apr 12 10:41:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76127, encodeId=cca1e612713, content=确实在术前谈话有必要去了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c781709303, createdName=WEIXIN9681ef9b, createdTime=Wed Apr 06 22:04:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446438, encodeId=fea61446438ec, content=<a href='/topic/show?id=2e3016e437' target=_blank style='color:#2F92EE;'>#AAN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1674, encryptionId=2e3016e437, topicName=AAN)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIt6X4iaHW8bDticcBSHUibNWk4Koe2icf0pdIOicSueicR3AKmviaSNPHkf9bCEicRK0anXEu3DjolU2EmkQ/132, createdBy=98ca5217513, createdName=bluefate123, createdTime=Sat Mar 26 08:16:00 CST 2016, time=2016-03-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=128613, encodeId=312d128613d4, content=不错哦,会学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 16 11:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633349, encodeId=859616333497c, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Mon Dec 26 10:16:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984872, encodeId=bd2d19848e201, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Wed Jan 04 12:16:00 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851301, encodeId=40c11851301a9, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri May 13 11:16:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82558, encodeId=e0988255871, content=应该了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sun Apr 24 21:35:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77489, encodeId=923ae7489cf, content=应了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Tue Apr 12 10:41:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76127, encodeId=cca1e612713, content=确实在术前谈话有必要去了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c781709303, createdName=WEIXIN9681ef9b, createdTime=Wed Apr 06 22:04:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446438, encodeId=fea61446438ec, content=<a href='/topic/show?id=2e3016e437' target=_blank style='color:#2F92EE;'>#AAN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1674, encryptionId=2e3016e437, topicName=AAN)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIt6X4iaHW8bDticcBSHUibNWk4Koe2icf0pdIOicSueicR3AKmviaSNPHkf9bCEicRK0anXEu3DjolU2EmkQ/132, createdBy=98ca5217513, createdName=bluefate123, createdTime=Sat Mar 26 08:16:00 CST 2016, time=2016-03-26, status=1, ipAttribution=)]
    2016-05-13 jklm09
  5. [GetPortalCommentsPageByObjectIdResponse(id=128613, encodeId=312d128613d4, content=不错哦,会学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 16 11:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633349, encodeId=859616333497c, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Mon Dec 26 10:16:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984872, encodeId=bd2d19848e201, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Wed Jan 04 12:16:00 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851301, encodeId=40c11851301a9, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri May 13 11:16:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82558, encodeId=e0988255871, content=应该了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sun Apr 24 21:35:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77489, encodeId=923ae7489cf, content=应了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Tue Apr 12 10:41:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76127, encodeId=cca1e612713, content=确实在术前谈话有必要去了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c781709303, createdName=WEIXIN9681ef9b, createdTime=Wed Apr 06 22:04:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446438, encodeId=fea61446438ec, content=<a href='/topic/show?id=2e3016e437' target=_blank style='color:#2F92EE;'>#AAN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1674, encryptionId=2e3016e437, topicName=AAN)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIt6X4iaHW8bDticcBSHUibNWk4Koe2icf0pdIOicSueicR3AKmviaSNPHkf9bCEicRK0anXEu3DjolU2EmkQ/132, createdBy=98ca5217513, createdName=bluefate123, createdTime=Sat Mar 26 08:16:00 CST 2016, time=2016-03-26, status=1, ipAttribution=)]
    2016-04-24 1de833cem82(暂无匿称)

    应该了解

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=128613, encodeId=312d128613d4, content=不错哦,会学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 16 11:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633349, encodeId=859616333497c, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Mon Dec 26 10:16:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984872, encodeId=bd2d19848e201, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Wed Jan 04 12:16:00 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851301, encodeId=40c11851301a9, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri May 13 11:16:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82558, encodeId=e0988255871, content=应该了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sun Apr 24 21:35:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77489, encodeId=923ae7489cf, content=应了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Tue Apr 12 10:41:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76127, encodeId=cca1e612713, content=确实在术前谈话有必要去了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c781709303, createdName=WEIXIN9681ef9b, createdTime=Wed Apr 06 22:04:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446438, encodeId=fea61446438ec, content=<a href='/topic/show?id=2e3016e437' target=_blank style='color:#2F92EE;'>#AAN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1674, encryptionId=2e3016e437, topicName=AAN)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIt6X4iaHW8bDticcBSHUibNWk4Koe2icf0pdIOicSueicR3AKmviaSNPHkf9bCEicRK0anXEu3DjolU2EmkQ/132, createdBy=98ca5217513, createdName=bluefate123, createdTime=Sat Mar 26 08:16:00 CST 2016, time=2016-03-26, status=1, ipAttribution=)]
    2016-04-12 Wechat4343a314

    应了解

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=128613, encodeId=312d128613d4, content=不错哦,会学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 16 11:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633349, encodeId=859616333497c, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Mon Dec 26 10:16:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984872, encodeId=bd2d19848e201, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Wed Jan 04 12:16:00 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851301, encodeId=40c11851301a9, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri May 13 11:16:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82558, encodeId=e0988255871, content=应该了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sun Apr 24 21:35:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77489, encodeId=923ae7489cf, content=应了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Tue Apr 12 10:41:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76127, encodeId=cca1e612713, content=确实在术前谈话有必要去了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c781709303, createdName=WEIXIN9681ef9b, createdTime=Wed Apr 06 22:04:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446438, encodeId=fea61446438ec, content=<a href='/topic/show?id=2e3016e437' target=_blank style='color:#2F92EE;'>#AAN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1674, encryptionId=2e3016e437, topicName=AAN)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIt6X4iaHW8bDticcBSHUibNWk4Koe2icf0pdIOicSueicR3AKmviaSNPHkf9bCEicRK0anXEu3DjolU2EmkQ/132, createdBy=98ca5217513, createdName=bluefate123, createdTime=Sat Mar 26 08:16:00 CST 2016, time=2016-03-26, status=1, ipAttribution=)]
    2016-04-06 WEIXIN9681ef9b

    确实在术前谈话有必要去了解

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=128613, encodeId=312d128613d4, content=不错哦,会学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Fri Sep 16 11:54:00 CST 2016, time=2016-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1633349, encodeId=859616333497c, content=<a href='/topic/show?id=377824e1c0' target=_blank style='color:#2F92EE;'>#ANA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2471, encryptionId=377824e1c0, topicName=ANA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=434d22047430, createdName=AspirantSuo, createdTime=Mon Dec 26 10:16:00 CST 2016, time=2016-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1984872, encodeId=bd2d19848e201, content=<a href='/topic/show?id=b9e21394eba' target=_blank style='color:#2F92EE;'>#PDE5抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13947, encryptionId=b9e21394eba, topicName=PDE5抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/lGEyfsKnIkkH93xUPMrUUycLh2XOfJJsphwPsVqDx8somSOepIFy9QE0MVAwDW3AS7V1epJ4tbPL9ADJLicvm8A/132, createdBy=b5132500067, createdName=ms55066533437992, createdTime=Wed Jan 04 12:16:00 CST 2017, time=2017-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1851301, encodeId=40c11851301a9, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Fri May 13 11:16:00 CST 2016, time=2016-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=82558, encodeId=e0988255871, content=应该了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8a711702117, createdName=1de833cem82(暂无匿称), createdTime=Sun Apr 24 21:35:00 CST 2016, time=2016-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77489, encodeId=923ae7489cf, content=应了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160412/IMG570C62AB017373724.jpg, createdBy=f6b41705718, createdName=Wechat4343a314, createdTime=Tue Apr 12 10:41:00 CST 2016, time=2016-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76127, encodeId=cca1e612713, content=确实在术前谈话有必要去了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c781709303, createdName=WEIXIN9681ef9b, createdTime=Wed Apr 06 22:04:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446438, encodeId=fea61446438ec, content=<a href='/topic/show?id=2e3016e437' target=_blank style='color:#2F92EE;'>#AAN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1674, encryptionId=2e3016e437, topicName=AAN)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIt6X4iaHW8bDticcBSHUibNWk4Koe2icf0pdIOicSueicR3AKmviaSNPHkf9bCEicRK0anXEu3DjolU2EmkQ/132, createdBy=98ca5217513, createdName=bluefate123, createdTime=Sat Mar 26 08:16:00 CST 2016, time=2016-03-26, status=1, ipAttribution=)]
    2016-03-26 bluefate123

相关资讯

打开脑袋唱歌?医学真是越来越神了

清醒开颅术 脑功能区 麻醉 传统开颅术

麻醉觉醒 手术刀下的恐怖体验

手术开始后,医生的手术刀划开他的皮肤,他忍受撕心裂肺的疼痛,却无法动一下,向医生们求救。“等等,先不要开始,我还能听见你们!”医生举起手术刀的一瞬间,患者拼命呐喊,但无论多么撕心裂肺的求救,都只有自己才能听到……什么是麻醉觉醒?为什么会发生这种可怕的状况?经历麻醉觉醒之后,会是什么状态?麻醉觉醒,你会中招吗?如何证实麻醉觉醒的发生?几个月前,笔者拟在全麻下行腰椎间盘手术,虽说已在医院上班多年,

麻醉、手术期心律失常的处理

围术期心律失常的处理原则 ①首先应确诊各类心律失常,再寻找其发生原因及相关诱因。 ②对严重而危及生命的心律失常应迅速处理,避免其恶化。上述心律失常包括多源性室早、室早R-on-T现象、室性心动过速、Ⅲ度房室传导阻滞及室率缓慢的Ⅱ度房室传导阻滞和室颤; ③应重视伴明显血流动力学改变的心律失常的处理,维持正常窦性心律或适宜的心室率。 一、快速型心律失常的处理 (一)窦

麻醉医生的自白: 产科麻醉,多的是你不知道的凶险!

“不就生个孩子嘛,你看张三家,李四家哪个不是那么生的,哪像你们说的那么危险恐怖。” 产科麻醉医生们最常听到的,就是这样的质疑——“生孩子难吗?看人家生的那么轻松,肯定不难。那既然这样,要你们麻醉医生做什么呢?” 其实医生真不是吓唬大家,如果所有产妇生产的都一样,那医生的确也就简单轻松多了。可问题是,也许麻醉医生们遇到的大部分孕妇生产情况都不一样呢? 产科麻醉的风险

Gastroenterology:结肠镜检查患者应尽量避免使用麻醉

目的:研究者旨在量化结肠镜检查有无麻醉的差异。方法:研究者进行了一项前瞻性队列研究和分析2008到2011健康研究数据库中的数据。研究者识别3168228名40-64岁进行结肠镜检查的男性和女性。校正年龄,性别,息肉位置,Charlson合并症指数,区域后,检测结肠镜检查30天内的并发症:包括结肠(如穿孔、出血、腹痛),麻醉相关(如肺炎、感染、并发症、麻醉),心肺功能的预后(即,低血压,心肌梗死,

Anesthesiology:婴儿期接受麻醉,患儿认知功能和情绪或改变

发表在Anesthesiology的一篇研究表明,孩子们若在婴儿期接受麻醉,则可能会造成他们情绪和行为发生变化,并产生焦虑,且会影响以后的生活。根据FDA数据,美国每年约有100万名4岁以下的儿童接受全麻手术。一些调查麻醉对儿童的影响的回顾性研究已经观察到,在婴儿期对患儿实施麻醉,有可能导致患儿今后出现认知功能障碍,并导致多种麻醉并发症的风险增加。其他动物研究也表明,动物幼崽若接受麻醉,则今后生活